Table 1.
Characteristics of included studies
| Study | N | Patients | Treatment | MF | DFS HR(95%CI) DD vs Con |
OS HR(95%CI) DD vs Con |
|---|---|---|---|---|---|---|
| Baldini 2003 | 150 | IIIA/B | dd(CEF → CMF/CEF) CEF → CMF/CEF |
5 years | 0.77(0.47–1.26) | 0.87(0.49–1.53) |
| CALGB 9741 | ||||||
| (1)Citron 2003 | 2005 | T0–3, N1–2, M0 | dd(A → P → C) A → P → C dd(AC → P) AC → P |
36 months | 0.74(0.59–0.93) | 0.69(050–0.93) |
| (2)Hudis 2005 | 69 months | 0.80(0.67–0.96) | 0.85(0.68–1.05) | |||
| MIG-1 | ||||||
| (1)Venturini 2005 | 1214 | pN+(≤ 10); pN− and high risk | ddFEC FEC |
10.4 years | 0.88(0.71–1.08) | 0.87(0.67–1.13) |
| (2)Giraudi 2016 | 15.8 years | 0.90(0.77–1.05) | 0.89(0.72–1.09) | |||
| GIM2 | 2091 | pN+(≥ 1) | dd(EC → P) EC → P dd(FEC → P) FEC → P |
7 years | 0.77(0.65–0.92) | 0.65(0.51–0.84) |
| Mastro 2015 | ||||||
| TACT2 | 4391 | ≥ 18 years; pN+; pN− and high risk (T0–3,N0–2,M0) |
ddE → CMF E → CMF ddE → X E → X |
85.6 months | NA | 1.04(0.88–1.21) |
| Cameron 2017 | ||||||
N number of patients, MF median follow-up, DFS disease-free survival, OS overall survival, HR hazard ratio, CI confidence interval, DD dose-dense chemotherapy, Con conventional chemotherapy, NA not available, CEF cyclophosphamide + epirubicin + 5-fluorouracil; CMF, cyclophosphamide + methotrexate + 5-fluorouracil, A doxorubicin, P paclitaxel, C cyclophosphamide, AC doxorubicin + cyclophosphamide, FEC 5-fluorouracil + epirubicin + cyclophosphamide, X capecitabine